Secondary prevention after myocardial infarction: a review of long-term trials.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004958:Estradiol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control*; D009539:Nicotinic Acids / Q000627:therapeutic use; D005082:Physical Exertion; D011446:Prospective Studies; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D004967:Estrogens; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D004958:Estradiol; D001241:Aspirin; D013442:Sulfinpyrazone